The Weight-Loss Drug Race Shifts From How Much to What Kind: Regeneron’s Add-On Cut Thigh-Muscle Loss by Up to 75%

The endocrinologist’s benchmark isn’t a number on a scale. Dr. Juan Pablo Frías wants his patients to “be able to bend down and tie your shoe without difficulty,” he told the Journal’s Alex Janin. The industry spent years measuring one thing — pounds lost. At a medical meeting in Milan, the measuring stick changed: which pounds. Lose a quarter of yourself in a hurry and some of it is muscle, and a retiree who sheds muscle is a retiree who falls. The next generation of drugs is being built to fix that — and Medicare is widening the door for retirees.

Today’s shots from Eli Lilly (LLY) and Novo Nordisk (NVO) take off 20% or more of body weight, on average, over about a year and a half at the highest doses. That race is largely won, so the field is differentiating. Regeneron (REGN) reported midstage data on a drug meant to ride alongside a GLP-1: patients lost about two-thirds to three-quarters less thigh muscle than those on semaglutide alone, and over 26 weeks the highest doses roughly halved the loss of lean mass. Novo’s CagriSema took 14.3% off Type 2 diabetics over roughly nine months with less fat around the liver and pancreas. Lilly’s retatrutide, which stripped as much as 28.3% in an earlier study, now comes with patients reporting better everyday movement.

The commercial logic is plain. A muscle-sparing add-on gives doctors a reason to prescribe and insurers a reason to pay for a second drug on top of the first, in a field where international GLP-1 patent filings rose 28% in the 12 months to March 2026. Skeptics aren’t sold. Columbia’s Wei Shen notes that lean mass isn’t the same as muscle, since it includes other nonfat tissue; other experts add that questionnaires about moving better don’t prove muscle was kept. Northwestern’s Dr. Nidhi Kansal puts it plainly: “We call them weight-loss drugs, but the goal medically is fat loss.”

Why this lands on the retirement budget

Janin’s line that matters most for our readers is almost an aside — body composition is especially critical for older adults “as many more gain access to weight-loss drugs through Medicare.” That’s the customer base being described. Osteoporosis and falls are the long tail of rapid loss, and they show up a decade later as a hip, a rehab stay and a question about who’s paying.

Our read

This is Health Costs first and Investments (IN04) second. Two drugs stacked where one used to be is two copays, and a retirement budget that pencils in today’s prescription spending as a flat line is lowballing it. The Part D out-of-pocket cap — $2,100 in the figures printed this week — is a ceiling on drug costs, not on the physical therapy, the walker or the care a fall brings. Muscle, it turns out, is the asset that keeps you out of long-term care, and protecting it will carry a price of its own. Plan for the drug line to rise, and keep the long-term-care question on the agenda rather than in the drawer.

On the books: Lilly is held at weight in 23 books and Novo in 11; Regeneron isn’t owned here. Nothing was added on midstage data — differentiation is also competition, and pricing pressure tends to arrive with it. The health-cost line in a plan ages faster than the owner does; it’s worth checking before the next open-enrollment window, not after the fall.